This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (110)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Surgical Oncology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Dominique Delbeke, MD, PhD; William H. Martin, MD; Martin P. Sandler, MD; William C. Chapman, MD; J. Kelly Wright, Jr, MD; C. Wright Pinson, MD, MBA

Arch Surg. 1998;133:510-516.

Background  In most malignant cells, the relatively low level of glucose-6-phosphatase leads to accumulation and trapping of [¹⁸F]fluorodeoxyglucose (FDG) intracellularly, allowing the visualization of increased uptake compared with normal cells.

Objectives  To assess the value of FDG positron emission tomography (PET) to differentiate benign from malignant hepatic lesions and to determine in which types of hepatic tumors PET can help evaluate stage, monitor response to therapy, and detect recurrence.

Design  Prospective blinded-comparison clinical cohort study.

Setting  Tertiary care university hospital and clinic.

Patients  One hundred ten consecutive referred patients with hepatic lesions 1 cm or larger on screening computed tomographic (CT) images who were seen for evaluation and potential resection underwent PET imaging. There were 60 men and 50 women with a mean (±SD) age of 59 ± 14 years. Follow-up was 100%.

Interventions  A PET scan using static imaging was performed on all patients. The PET scan imaging and biopsy, surgery, or both were performed, providing pathological samples within 2 months of PET imaging. All PET images were correlated with CT scan to localize the lesion. However, PET investigators were unaware of any previous interpretation of the CT scan.

Main Outcome Measures  Visual interpretation, lesion-to-normal liver background (L/B) ratio of radioactivity, and standard uptake value (SUV) were correlated with pathological diagnosis.

Results  All (100%) liver metastases from adenocarcinoma and sarcoma primaries in 66 patients and all cholangiocarcinomas in 8 patients had increased uptake values, L/B ratios greater than 2, and an SUV greater than 3.5. Hepatocellular carcinoma had increased FDG uptake in 16 of 23 patients and poor uptake in 7 patients. All benign hepatic lesions (n = 23), including adenoma and fibronodular hyperplasia, had poor uptake, an L/B ratio of less than 2, and an SUV less than 3.5, except for 1 of 3 abscesses that had definite uptake.

Conclusions  The PET technique using FDG static imaging was useful to differentiate malignant from benign lesions in the liver. Limitations include false-positive results in a minority of abscesses and false-negative results in a minority of hepatocellular carcinoma. The PET technique was useful in tumor staging and detection of recurrence, as well as monitoring response to therapy for all adenocarcinomas and sarcomas and most hepatocellular carcinomas. Therefore, pretherapy PET imaging is recommended to help assess new hepatic lesions.

From the Section of Nuclear Medicine, Department of Radiology and Radiological Sciences (Drs Delbeke, Martin, and Sandler), and the Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery (Drs Chapman, Wright, and Pinson), Vanderbilt University Medical Center, Nashville, Tenn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Detection of Hepatocellular Carcinoma Using 11C-Choline PET: Comparison with 18F-FDG PET
Yamamoto et al.
JNM 2008;49:1245-1248.
ABSTRACT | FULL TEXT  

Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms
He and Guo
Postgrad. Med. J. 2008;84:246-251.
ABSTRACT | FULL TEXT  

Staging Pathways in Recurrent Colorectal Carcinoma: Is Contrast-Enhanced 18F-FDG PET/CT the Diagnostic Tool of Choice?
Soyka et al.
JNM 2008;49:354-361.
ABSTRACT | FULL TEXT  

Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Predicts Tumor Differentiation, P-glycoprotein Expression, and Outcome after Resection in Hepatocellular Carcinoma
Seo et al.
Clin. Cancer Res. 2007;13:427-433.
ABSTRACT | FULL TEXT  

Diagnostic Accuracy of Colorectal Cancer Staging With Whole-Body PET/CT Colonography
Veit-Haibach et al.
JAMA 2006;296:2590-2600.
ABSTRACT | FULL TEXT  

Detection of Klatskin's Tumor in Extrahepatic Bile Duct Strictures Using Delayed 18F-FDG PET/CT: Preliminary Results for 22 Patient Studies
Reinhardt et al.
JNM 2005;46:1158-1163.
ABSTRACT | FULL TEXT  

Diagnostic Value and Limitations of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Cartilaginous Tumors of Bone
Lee et al.
JBJS 2004;86:2677-2685.
ABSTRACT | FULL TEXT  

The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
Schrevens et al.
The Oncologist 2004;9:633-643.
ABSTRACT | FULL TEXT  

Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3'-Fluoro-3'-Deoxy-L-Thymidine
Cobben et al.
Clin. Cancer Res. 2004;10:1685-1690.
ABSTRACT | FULL TEXT  

Diagnosis and Treatment of Cholangiocarcinoma
Anderson et al.
The Oncologist 2004;9:43-57.
ABSTRACT | FULL TEXT  

Direct Comparison of 18F-FDG PET and PET/CT in Patients with Colorectal Carcinoma
Cohade et al.
JNM 2003;44:1797-1803.
ABSTRACT | FULL TEXT  

18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies
Chin and Wahl
Gut 2003;52:iv23-29.
ABSTRACT | FULL TEXT  

11C-Acetate PET Imaging in Hepatocellular Carcinoma and Other Liver Masses
Ho et al.
JNM 2003;44:213-221.
ABSTRACT | FULL TEXT  

11C-Acetate: A New Tracer for the Evaluation of Hepatocellular Carcinoma
Delbeke and Pinson
JNM 2003;44:222-223.
FULL TEXT  

Detection of Primary Hepatic Malignancy in Liver Transplant Candidates: Prospective Comparison of CT, MR Imaging, US, and PET
Teefey et al.
Radiology 2003;226:533-542.
ABSTRACT | FULL TEXT  

Value of Positron Emission Tomography With [F-18]Fluorodeoxyglucose in Patients With Colorectal Liver Metastases: A Prospective Study
Ruers et al.
JCO 2002;20:388-395.
ABSTRACT | FULL TEXT  

Quantification of [18F]FDG Uptake in the Normal Liver Using Dynamic PET: Impact and Modeling of the Dual Hepatic Blood Supply
Brix et al.
JNM 2001;42:1265-1273.
ABSTRACT | FULL TEXT  

A Tabulated Summary of the FDG PET Literature
Gambhir et al.
JNM 2001;42:1S-93.
FULL TEXT  

The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
Vansteenkiste and Stroobants
Eur Respir J 2001;17:802-820.
ABSTRACT | FULL TEXT  

Biliary Tract Cancers
de Groen et al.
NEJM 1999;341:1368-1378.
FULL TEXT  

Staging Non-Small Cell Lung Cancer with Whole-Body PET
Marom et al.
Radiology 1999;212:803-809.
ABSTRACT | FULL TEXT